Bristol Myers Squibb Presents First Phase 3 KarXT Data in Alzheimer’s Psychosis
The company presented first clinical data from two Phase 3 ADEPT studies evaluating KarXT for psychosis associated with Alzheimer’s disease. Preliminary ADEPT-1 findings from a 12-week open-label lead-in period showed observed improvements.